Valuation: Cingulate Inc.

Market Cap 64.52M 56.08M 52.2M 47.93M 90.51M 6.16B 91.91M 615M 241M 3.07B 242M 237M 10.28B P/E 2026 *
-2.04x
P/E 2027 * -4.77x
Enterprise Value 64.52M 56.08M 52.2M 47.93M 90.51M 6.16B 91.91M 615M 241M 3.07B 242M 237M 10.28B EV / Sales 2026 *
22.3x
EV / Sales 2027 * 3.22x
Free-Float
69.46%
Yield 2026 *
-
Yield 2027 * -
1 day+0.63%
1 week+3.23%
1 month-18.68%
3 months-10.80%
6 months-16.55%
Current year+10.37%
1 week 4.24
Extreme 4.245
4.85
1 month 4.2
Extreme 4.195
5.65
Current year 3.16
Extreme 3.16
11.89
1 year 3.16
Extreme 3.16
11.89
3 years 1.8
Extreme 1.8001
187.2
5 years 1.8
Extreme 1.8001
1,236
10 years 1.8
Extreme 1.8001
1,236
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 63 2017-12-31
Chief Executive Officer 51 2012-04-30
Chief Tech/Sci/R&D Officer 69 2017-12-31
Director TitleAgeSince
Director/Board Member 87 2018-05-31
Director/Board Member 60 2024-02-12
Chairman 51 2012-04-30
Date Insider Type Main position Quantity % Market Cap.
7/16/26 Free

Director

20,000 0.1485%
7/16/26 Free

Founder

80,000 0.5940%
7/16/26 Free

Executive/Senior Manager

100,000 0.7424%
Change 5-day change 1-year change 3-year change Capi.($)
+0.63%+3.23%-6.08%-96.40% 64.52M
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+411.96%+495.33% 39.87B
-1.16%+12.96%+28.81%+7.25% 38.68B
-1.88%-3.03%+5.69%+53.00% 35.13B
-1.74%+5.12%+14.44%+41.77% 29.79B
-0.21%-4.04%+36.40%+125.75% 16.11B
-2.85%-3.92% - - 16.08B
-0.64%+2.65%+3.40%+13.11% 13.61B
-1.19%-1.32%-1.73%-34.37% 12.62B
Average -1.28%+1.27%+54.58%+68.53% 25.05B
Weighted average by Cap. -1.60%+2.03%+79.76%+108.56%

Financials

2026 *2027 *
Net sales 2.89M 2.52M 2.34M 2.15M 4.06M 276M 4.12M 27.6M 10.83M 138M 10.87M 10.63M 461M 20.04M 17.42M 16.21M 14.88M 28.11M 1.91B 28.54M 191M 75M 952M 75.25M 73.59M 3.19B
Net income -29.32M -25.49M -23.73M -21.78M -41.14M -2.8B -41.78M -280M -110M -1.39B -110M -108M -4.67B -13.31M -11.57M -10.77M -9.89M -18.68M -1.27B -18.96M -127M -49.83M -633M -50M -48.9M -2.12B
Net Debt - -
Logo Cingulate Inc.
Cingulate Inc. is a biopharmaceutical company. The Company offers Precision Timed Release (PTR), which is a drug delivery platform technology to build and advance a pipeline of pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety. Its PTR platform incorporates an erosion barrier layer (EBL) designed to allow for the release of drug substances at specific, pre-defined time intervals. It develops stimulant medications which include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of ADHD across all three patient segments: children (aged 6 -12), adolescents (aged 13-17), and adults (aged 18+). It also develops CTx-2103 (buspirone), for the treatment of anxiety.
Employees
14
Date Price Change Volume
26-07-31 US$4.790 +0.63% 60,629
26-07-30 US$4.760 +5.19% 124,726
26-07-29 US$4.525 -0.11% 125,302
26-07-28 US$4.530 +0.22% 239,637
26-07-27 US$4.520 -2.59% 151,287
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.790USD
Average target price
23.00USD
Spread / Average Target
+380.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CING Stock